{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T21:31:32Z","timestamp":1777066292724,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00520-024-08361-1","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T17:02:07Z","timestamp":1708102927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment patterns and outcomes of high-grade immune checkpoint inhibitor-related pneumonitis in an oncology hospitalist service"],"prefix":"10.1007","volume":"32","author":[{"given":"Joanna-Grace M.","family":"Manzano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadeel","family":"Sahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Aldrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahran","family":"Shoukier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine B.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kodwo","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwame","family":"Koom-Dadzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Kheder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C","family":"Franco Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayoora","family":"Muthu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Simbaqueba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle Sibille","family":"Senechalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman","family":"Brito-Dellan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"8361_CR1","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1200\/EDBK_201319","volume":"38","author":"S Zimmermann","year":"2018","unstructured":"Zimmermann S et al (2018) Immune checkpoint inhibitors in the management of lung cancer. Am Soc Clin Oncol Educ Book 38:682\u2013695","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"8361_CR2","first-page":"185","volume":"41","author":"W Alexander","year":"2016","unstructured":"Alexander W (2016) The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge. P T 41(3):185\u2013191","journal-title":"P T"},{"issue":"23","key":"8361_CR3","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220\u20132229","journal-title":"N Engl J Med"},{"issue":"11","key":"8361_CR4","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1007\/s00262-021-02996-3","volume":"70","author":"E Suazo-Zepeda","year":"2021","unstructured":"Suazo-Zepeda E et al (2021) Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Immunol Immunother 70(11):3069\u20133080","journal-title":"Cancer Immunol Immunother"},{"key":"8361_CR5","unstructured":"NCCN. National Comprehensive Cancer Network Guidelines in Oncology: management of immunotherapy-related toxicities. 2022 February 10, 2023]; Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf"},{"issue":"4","key":"8361_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/MCP.0000000000000689","volume":"26","author":"VR Shannon","year":"2020","unstructured":"Shannon VR (2020) Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer. Curr Opin Pulm Med 26(4):326\u2013340","journal-title":"Curr Opin Pulm Med"},{"issue":"12","key":"8361_CR7","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20131728","journal-title":"JAMA Oncol"},{"key":"8361_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/jitc-2022-004670","volume":"10","author":"BC Tiu","year":"2022","unstructured":"Tiu BC et al (2022) Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. J Immunother Cancer 10:6","journal-title":"J Immunother Cancer"},{"issue":"12","key":"8361_CR9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J et al (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol 33(12):1217\u20131238","journal-title":"Ann Oncol"},{"key":"8361_CR10","unstructured":"MASCC.org. 2020 clinical practice recommendations for the management of immune-mediated adverse events from checkpoint inhibitors. 2020 [cited 2023; Available from: https:\/\/mascc.org\/2020-clinical-practice-recommendations-for-the-management-of-immune-mediated-adverse-events-from-checkpoint-inhibitors\/"},{"issue":"6","key":"8361_CR11","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1164\/rccm.201906-1202ST","volume":"200","author":"CR Sears","year":"2019","unstructured":"Sears CR et al (2019) Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med 200(6):e31\u2013e43","journal-title":"Am J Respir Crit Care Med"},{"key":"8361_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/978-3-030-41008-7_13","volume":"1244","author":"L Zhong","year":"2020","unstructured":"Zhong L et al (2020) Immune-related adverse events: pneumonitis. Adv Exp Med Biol 1244:255\u2013269","journal-title":"Adv Exp Med Biol"},{"issue":"17","key":"8361_CR13","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36(17):1714\u20131768","journal-title":"J Clin Oncol"},{"issue":"1","key":"8361_CR14","doi-asserted-by":"publisher","first-page":"e000381","DOI":"10.1136\/bmjoq-2018-000381","volume":"8","author":"JG Manzano","year":"2019","unstructured":"Manzano JG et al (2019) Demonstrating value: association of cost and quality outcomes with implementation of a value-driven oncology-hospitalist inpatient collaboration for patients with lung cancer. BMJ Open Qual 8(1):e000381","journal-title":"BMJ Open Qual"},{"key":"8361_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.lungcan.2019.05.029","volume":"134","author":"U Dafni","year":"2019","unstructured":"Dafni U et al (2019) Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer 134:127\u2013140","journal-title":"Lung Cancer"},{"issue":"5.5","key":"8361_CR16","first-page":"574","volume":"17","author":"MA Gubens","year":"2019","unstructured":"Gubens MA, Davies M (2019) NCCN guidelines updates: new immunotherapy strategies for improving outcomes in non-small cell lung cancer. J Natl Compr Canc Netw 17(5.5):574\u2013578","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"8361_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12885-023-10649-0","volume":"23","author":"L Pang","year":"2023","unstructured":"Pang L et al (2023) Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. BMC Cancer 23(1):203","journal-title":"BMC Cancer"},{"issue":"3","key":"8361_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jtho.2018.11.016","volume":"14","author":"K Suresh","year":"2019","unstructured":"Suresh K et al (2019) Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J Thorac Oncol 14(3):494\u2013502","journal-title":"J Thorac Oncol"},{"issue":"2","key":"8361_CR19","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.chest.2021.02.032","volume":"160","author":"WT Atchley","year":"2021","unstructured":"Atchley WT et al (2021) Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina. Chest 160(2):731\u2013742","journal-title":"Chest"},{"issue":"7","key":"8361_CR20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J et al (2017) Pneumonitis in patients treated with anti\u2013programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 35(7):709\u2013717","journal-title":"J Clin Oncol"},{"issue":"9","key":"8361_CR21","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1200\/JOP.18.00703","volume":"15","author":"A Balaji","year":"2019","unstructured":"Balaji A et al (2019) Immune-related adverse events requiring hospitalization: spectrum of toxicity, treatment, and outcomes. J Oncol Pract 15(9):e825\u2013e834","journal-title":"J Oncol Pract"},{"issue":"6","key":"8361_CR22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.6004\/jnccn.2018.7268","volume":"17","author":"J Naidoo","year":"2019","unstructured":"Naidoo J et al (2019) A multidisciplinary toxicity team for cancer immunotherapy-related adverse events. J Natl Compr Canc Netw 17(6):712\u2013720","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"8361_CR23","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/1078-0432.CCR-21-1240","volume":"28","author":"JW Smithy","year":"2022","unstructured":"Smithy JW, Faleck DM, Postow MA (2022) Facts and hopes in prediction, diagnosis, and treatment of immune-related adverse events. Clin Cancer Res 28(7):1250\u20131257","journal-title":"Clin Cancer Res"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08361-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08361-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08361-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T08:14:32Z","timestamp":1711008872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08361-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["8361"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08361-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"25 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Quality Improvement Assessment Board at our institution approved this study. Ethical approval was not required by the reviewing\/approving body.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable. There is no patient identifiable data in this publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Maggie Lu has the following declarations outside the submitted work holds stock with Amgen. The authors have no other relevant disclosures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"160"}}